Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?

Future Oncology

Volumn 6, Issue 9, 2010, Pages 1407-1414

  Weller, Michael ^a   Wick, Wolfgang ^b   Hegi, Monika E ^c,d   Stupp, Roger ^c,d   Tabatabai, Ghazaleh ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

biomarker; chemotherapy; glioblastoma; IDH1; MGMT

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CD133 ANTIGEN; CEDIRANIB; COLLAGEN TYPE 4; ENZASTAURIN; ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; TEMOZOLOMIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CANCER CHEMOTHERAPY; CEREBROSPINAL FLUID; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL RESEARCH; CLINICAL TRIAL; CYTOTOXICITY; DISEASE MARKER; GENE DELETION; GENERAL PRACTICE; GLIOBLASTOMA; HUMAN; METHYLATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; INDIVIDUALIZED MEDICINE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 77957958048     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.113     Document Type: Review

References (62)

1. Yung WKA, Albright RE, Olson J et al.: A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 588-593 (2000).
2. Stupp R, Mason WP, van den Bent MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
3. Stupp R, Hegi ME, Mason WP et al.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
4. Hegi ME, Diserens AC, Gorlia T et al.: MGMT gene silencing and response to temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).
5. Wick W, Engel C, Combs SE et al.: NOA-08 randomized Phase III trial of 1-week-on/1- week-off temozolomide versus involved field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). J. Clin. Oncol. 28(7 Suppl.) (2010) (Abstract LBA2001).
6. Grossmann SA, Ye X, Chamberlain M et al.: Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter Phase II trial. J. Clin. Oncol. 27, 4155-4161 (2009).
7. Stupp R, Hegi ME, Neyns B et al.: Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 2712-2718 (2010).
8. Wick A, Felsberg J, Steinbach JP et al.: Efficacy and tolerability of temozolomide in an one week on/one week off regimen in patients with recurrent glioma. J. Clin. Oncol. 25, 3357-3361 (2007).
9. Perry JR, Belanger K, Mason WP et al.: Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma. J. Clin. Oncol. 28, 2051-2057 (2010).
10. The Cancer Genome Atlas Consortium: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
11. Parsons DW, Jones S, Zhang X et al.: An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
12. Weller M, Felsberg J, Hartmann C et al.: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma. A prospective translational study of the German Glioma Network. J. Clin. Oncol. 27, 5743-5750 (2009).
13. Verhaak RG, Hoadley KA, Purdom E et al.: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
14. Haas-Kogan DA, Prados MD, Tihan T et al.: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst. 97, 880-887 (2005).
15. Mellinghoff IK, Wang MY, Vivanco I et al.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
16. Van den Bent MJ, Brandes AA, Rampling R et al.: Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group study 26034. J. Clin. Oncol. 27, 1268-1274 (2009).
17. Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R: Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin. Cancer Res. 14, 957-960 (2008).
18. Heimberger AB, Sampson JH: The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin. Biol. Ther. 9, 1087-1098 (2009).
19. Jenkins RB, Blair H, Ballman KV et al.: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66, 9852-9861 (2006).
20. Cairncross JG, Ueki K, Zlatescu MC et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 90, 1473-1479 (1998).
21. Cairncross G, Berkey B, Shaw E et al.: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol. 24, 2707-2714 (2006).
22. Van den Bent MJ, Carpentier AF, Brandes AA et al.: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol. 24, 2715-2722 (2006).
23. Wick W, Hartmann C, Engel C et al.: NOA-04 randomized Phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J. Clin. Oncol. 27, 5874-5880 (2009).
24. Jaeckle KA, Eyre HJ, Jeannette J et al.: Correlation of tumor O6 methylguanine- DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis- chloroethylnitrosourea: a Southwest Oncology Group study. J. Clin. Oncol. 16, 3310-3315 (1998).
25. Weller M, Stupp R, Reifenberger G et al.: MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Rev. Neurol. 6, 39-51 (2010).
26. Esteller M, Garcia-Foncillas J, Andion E et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354 (2000).
27. Hegi ME, Diserens AC, Godard S et al.: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 10, 1871-1874 (2004).
28. Preusser M, Janzer RC, Felsberg J et al.: Anti-O6-methylguanine- methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 18, 520-532 (2008).
29. Grasbon-Frodl EM, Kreth FW, Ruiter M et al.: Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int. J. Cancer 121, 2458-2464 (2007).
30. Brandes AA, Franceschi E, Tosoni A et al.: O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro-Oncology 12, 283-288 (2010).
31. Tonn J, Felsberg J, Thon N et al.: MGMT promoter methylation status and DNA mismatch repair genes in paired primary and recurrent glioblastoma: a translational study of the German Glioma Network. J. Clin. Oncol. 28(15 Suppl.) Abstr. 2076 (2010).
32. Zhao S, Lin Y, Xu W et al.: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1a. Science 324, 261-265 (2009).
33. Dang L, White DW, Gross S et al.: Cancerassociated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744 (2009).
34. Frezza C, Tennant DA, Gottlieb E: IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell 17, 7-9 (2010).
35. Yan H, Parsons DW, Jin G et al.: IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
36. Capper D, Weissert S, Balss J et al.: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 20, 245-254 (2010).
37. Noushmehr H, Weisenberger DJ, Diefes K et al.: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).
38. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
39. Singh SK, Hawkins C, Clarke ID et al.: Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
40. Clement V, Marino D, Cudalbu C et al.: Marker-independent identification of gliomainitiating cells. Nature Methods 7, 224-228 (2010).
41. Son MJ, Woolard K, Nam DH, Lee J, Fine HA: SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4, 440-452 (2009).
42. Bao S, Wu Q, McLendon RE et al.: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756.760 (2006).
43. Pallini R, Ricci-Vitiani L, Banna GL et al.: Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin. Cancer Res. 14, 8205.8212 (2008).
44. Schwartzbaum JA, Huang K, Lawler S, Ding B, Yu J, Chiocca EA: Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro-Oncology 12, 320.327 (2010).
45. Murat A, Migliavacca E, Gorlia T et al.: Stem cell-related eself-renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol. 26, 3015.3024 (2008).
46. Clement V, Dutoit V, Marino D et al.: Limits of CD133 as a marker of glioma self-renewing cells. Int. J. Cancer 125, 244.248 (2009).
47. Griguer CE, Oliva CR, Gobin E et al.: CD133 is a marker of bioenergetic stress in human glioma. PLoS One 3, E3655 (2008).
48. Essers MA, Offner S, Blanco-Bose WE et al.: IFNa activates dormant haematopoietic stem cells in vivo. Nature 458, 904.908 (2009).
49. Weaver KD, Grossman SA, Herman JG: Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest. 24, 35.40 (2006).
50. Wakabayashi T, Natsume A, Hatano H et al.: p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. Neurosurgery 64, 455.461 (2009).
51. Liu BL, Cheng JX, Zhang W et al.: Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro- Oncology 12, 540.548 (2010).
52. Balana C, Ramirez JL, Taron M et al.: O6-methyl-guanine-DNA methyltransferasemethylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin. Cancer Res. 9, 1461.1468 (2003).
53. Lavon I, Refael M, Zelikovitch B et al.: Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-Oncology 12, 173.180 (2010).
54. Tanwar MK, Gilbert MR, Holland EC: Gene expression microarray analysis reveals YKL.40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 62, 4364.4368 (2002).
55. Johansen JS, Vittrup Jensen B, Roslind A et al.: Serum YKL.40, a new prognostic biomarker in cancer patients? Cancer Epidemiol. Biomarkers Prev. 15, 194.202 (2006).
56. Hormigo A, Gu B, Karimi S et al.: YKL.40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with highgrade gliomas. Clin. Cancer Res. 12, 5698.5704 (2006).
57. Batchelor TT, Sorensen AG, di Tomaso E et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastomas patients. Cancer Cell 11, 83.95 (2007).
58. Sorensen AG, Batchelor TT, Zhang WT et al.: A 'evascular normalization index'f as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69, 5296.5300 (2009).
59. Gartner W, Ilhan A, Neziri D et al.: Elevated blood markers 1 year before manifestation of malignant glioma. Neuro-Oncology DOI: 10.1093/neuonc/noq034 (2010) (Epub ahead of print).
60. Lawler S, Chiocca EA: Emerging functions of microRNAs in glioblastoma. J. Neurooncol. 92, 297.306 (2009).
61. Ludwig N, Keller A, Heisel S et al.: Improving seroreactivity-based detection of glioma. Neoplasia 11, 1383.1389 (2009).
62. Shnaper S, Desbaillets I, Brown DA et al.: Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int. J. Cancer 125, 2624.2630 (2009).